FDA Claims Sole Authority Over Naming Of US-Licensed Biologics
Executive Summary
Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.
You may also be interested in...
US FDA Vs. USP: Regulator Sees Biologic Product Monographs As Barrier To Biosimilars
USP's proposed change aimed at harmonizing with FDA's suffix-based naming system for biologics would 'aggravate existing concerns' that biologic product-specific monographs are too inflexible and may impede development of biosimilars, agency says in a letter publicized through a tweet by the commissioner.
US FDA Vs. USP: Regulator Sees Biologic Product Monographs As Barrier To Biosimilars
USP's proposed change aimed at harmonizing with FDA's suffix-based naming system for biologics would 'aggravate existing concerns' that biologic product-specific monographs are too inflexible and may impede development of biosimilars, agency says in a letter publicized through a tweet by the commissioner.
How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Drug Review Profile examines how Amgen persuaded US agency that its preferred distinguishable suffix choice for Amjevita, a biosimilar to AbbVie’s Humira, would not be confused with medical abbreviations or existing trademarks.